Abstract:Gene-based virotherapy mediated by oncolytic viruses is currently experiencing a renaissance in cancer therapy. However, relatively little attention has been given to the potentiality of dual gene virotherapy strategy as a novel therapeutic approach to mediate triplex anticancer combination effects, particularly if the two suitable genes are well chosen. Both tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and interleukin-12 (IL-12) have been emerged as promising pharmacological candidates in cancer therapy; however, the combined efficacy of TRAIL and IL-12 genes for treatment of human hepatocellular carcinoma (HCC) remains to be determined.Herein, we investigated the therapeutic efficacy of concurrent therapy with two armed oncolytic adenoviruses encoding human TRAIL gene (Ad-ΔB/TRAIL) and IL-12 gene (Ad-ΔB/IL-12), respectively, on preclinical models of human HCC, and also elucidated the possible underlying mechanisms. The effects of Ad-ΔB/TRAIL+Ad-ΔB/IL-12 combination therapy were assessed both in vitro on Hep3B and HuH7 human HCC cell lines and in vivo on HCC-orthotopic model established in the livers of athymic nude mice by intrahepatic implantation of human Hep3B cells.Compared to therapy with non-armed control Ad-ΔB, combined therapy with Ad-ΔB/TRAIL+Ad-ΔB/IL-12 elicited profound anti-HCC killing effects on Hep3B and HuH7 cells and on the transplanted Hep3B-orthotopic model. Efficient viral replication and TRAIL and IL-12 expression were also confirmed in HCC cells and the harvested tumor tissues treated with this combination therapy. Mechanistically, co-therapy with Ad-ΔB/TRAIL+Ad-ΔB/IL-12 exhibited an enhanced effect on apoptosis promotion, activation of caspase-3 and-8, generation of anti-tumor immune response evidenced by upregulation of interferon gamma (IFN-γ) production and infiltration of natural killer-and antigen presenting cells, and remarkable repression of intratumor vascular endothelial growth factor (VEGF) and cluster of differentiation 31 (CD31) expression and tumor microvessel density.Overall, our data showed a favorable therapeutic effect of Ad-ΔB/TRAIL+Ad-ΔB/IL-12 combination therapy against human HCC, and may therefore constitute a promising and effective therapeutic strategy for treating human HCC. However, further studies are warranted for its reliable clinical translation.

A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma

Conditionally Replicative Adenovirus Vector Carrying Trail Gene For Enhanced Oncolysis Of Human Hepatocellular Carcinoma

Targeted Expression of Green Fluorescent Protein/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Fusion Protein from Human Telomerase Reverse Transcriptase Promoter Elicits Antitumor Activity Without Toxic Effects on Primary Human Hepatocytes

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation.

Anti-liver Cancer Activity of TNF-related Apoptosis-Inducing Ligand Gene and Its Bystander Effects.

Gene-viro-therapy Targeting Liver Cancer by a Dual-Regulated Oncolytic Adenoviral Vector Harboring IL-24 and TRAIL

Fiber-modified Adenoviral Vector Expressing the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Gene from the Human Telomerase Reverse Transcriptase Promoter Induces Apoptosis in Human Hepatocellular Carcinoma Cells

Adenovirus-mediated Tissue-Specific Cytosine Deaminase Gene Therapy for Human Hepatocellular Carcinoma with Different AFP Expression Levels.

AAV-mediated TRAIL Gene Expression Driven by Htert Promoter Suppressed Human Hepatocellular Carcinoma Growth in Mice

Potent Antitumor Effect of Trail Mediated by A Novel Adeno-Associated Viral Vector Targeting to Telomerase Activity for Human Hepatocellular Carcinoma

Recombinant Adeno-Associated Virus-Mediated Trail Gene Therapy Suppresses Liver Metastatic Tumors

Cell-Specific Expression of Artificial Micrornas Targeting Essential Genes Exhibit Potent Antitumor Effect on Hepatocellular Carcinoma Cells

Combined Therapy with Oncolytic Adenoviruses Encoding TRAIL and IL-12 Genes Markedly Suppressed Human Hepatocellular Carcinoma Both in Vitro and in an Orthotopic Transplanted Mouse Model

Construction of Recombinant Adenovirus Containing Soluble Tumor Necrosis Factor-related Apoptosis-inducing Ligand Gene and its Expression in Liver Cancer Cell Line

Construction of Conditionally Replication-Competent Adenoviral Vectors Targeting Hepatocarcinoma and Their in Vitro Anti-Tumor Effect

Oral Adeno-Associated Virus-Strail Gene Therapy Suppresses Human Hepatocellular Carcinoma Growth in Mice

Construction of a regulable gene therapy vector targeting for hepatocellular carcinoma

DNA Polymerases as targets for gene therapy of hepatocellular carcinoma

The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma

Gene Therapy Targeting Hepatocellular Carcinoma by A Dual-Regulated Oncolytic Adenovirus Harboring the Focal Adhesion Kinase Shrna